Nachrichten und Videos - INNATE PHARMA - Seite 3

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq: IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui son chiffre d’affaires et sa position de trésorerie pour les trois premiers mois de l’année 2023. « Notre solide position de trésorerie a été renforcée au cours du premier trimestre 2023 grâce à un accord de licence avec Takeda pour des anticorps conjugués (ADC) générés à partir d’un panel d'anticorps développés par Innate, principalement...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its consolidated financial results for the quarter ending March 31, 2023. “ Our strong cash position was further bolstered during the first quarter of 2023 as we signed a license agreement with Takeda for antibody drug conjugates (ADC) using a panel of selected Innate antibodies, with a primary focus in Celiac disease. This agreement demonstrates our ability to expand...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its consolidated financial results for the quarter ending March 31, 2023. “ Our strong cash position was further bolstered during the first quarter of 2023 as we signed a license agreement with Takeda for antibody drug conjugates (ADC) using a panel of selected Innate antibodies, with a primary focus in Celiac disease. This agreement demonstrates our ability to expand the application of...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at May 1, 2023: Total number of shares outstanding: 80,450,212 ordinary shares 6,514 Preferred Shares...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at May 1, 2023: Total number of shares outstanding: 80,450,212 ordinary shares 6,514 Preferred Shares 2016 7,581...

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1 er mai 2023 : Nombre d’actions composant le capital : 80 450 212 actions ordinaires 6 514 Actions de Préférence 2016 7 581...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy &...

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd'hui qu'elle organisera une conférence téléphonique le mercredi 10 mai 2023 à 14h00 CEST / 8h00 EDT afin de présenter ses résultats financiers et l’avancée de son portefeuille au premier trimestre 2023. La conférence sera animée par : Mondher Mahjoubi, Président du Directoire Joyson Karakunnel, Vice-président exécutif, Directeur Médical Yannis Morel,...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One abstract for SAR’579, currently developed by Sanofi, has been selected for oral presentation. SAR’579 is a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123 using...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today three abstracts including Innate’s product candidates have been accepted for the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One abstract for SAR’579, currently developed by Sanofi, has been selected for oral presentation. SAR’579 is a potential first-in-class NKp46/CD16-based NK cell engager...

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que trois abstracts avec plusieurs de ses candidats-médicaments ont été acceptés pour le congrès annuel 2023 de l'American Society for Clinical Oncology (ASCO) qui se tiendra du 2 au 6 juin 2023 à Chicago (Etats-Unis). Un abstract pour SAR'579, en cours de développement par Sanofi, a été sélectionné pour une présentation orale. SAR’579 est un NK Cell...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product...

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd'hui qu'elle a déposé auprès de la Securities and Exchange Commission (« SEC ») un « prospectus supplement » relatif à un nouveau programme At-The-Market (« ATM »). Dans le cadre de ce programme, la Société peut émettre et vendre à des investisseurs éligibles (tels que décrits ci-dessous) un montant brut total allant jusqu'à 75 millions de dollars d'...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to a new At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (“ADS”), each ADS representing one ordinary share of Innate,...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to a new At-The-Market (“ATM”) program. Pursuant to this program, the Company may offer and sell to eligible investors (as described below) a total gross amount of up to $75 million of American Depositary Shares (“ADS”), each ADS representing one ordinary...

Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des membres de son équipe de direction seront présents à la conférence investisseurs suivante : Van Lanschot Kempen Life Sciences Conference 2023 Date : 25-26 avril, Amsterdam À propos d’Innate Pharma : Innate Pharma S.A. est une société de biotechnologies au stade clinique qui développe des traitements d’immunothérapies contre le cancer. Son...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conference: Van Lanschot Kempen Life Sciences Conference 2023 Event Date: April 25-26, Amsterdam About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming investor conference: Van Lanschot Kempen Life Sciences Conference 2023 Event Date: April 25-26, Amsterdam About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to...

Regulatory News: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1 er avril 2023 : Nombre d’actions composant le capital : 80 222 007 actions ordinaires 6 514 Actions de Préférence 2016 7 581...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) releases its total number of shares outstanding as well as its voting rights as at April 1, 2023: Total number of shares outstanding: 80,222,007 ordinary shares 6,514 Preferred Shares 2016 7,581...